Real-World Experience With Dapagliflozin in Non-diabetic Chronic Kidney Disease: A Case Series From India
Abstract
Introduction: Sodium-glucose cotransporter-2 inhibitors (SGLT2is), including dapagliflozin, have demonstrated reno-protective effects independent of glycemic control in chronic kidney disease (CKD). The data presented here add to the already available evidence on the use of dapagliflozin in patients with non-diabetic kidney disease Methods: Non-diabetic CKD patients treated with dapagliflozin at a tertiary care center in India were included in the case series. Data for parameters, including renal function (estimated glomerular filtration rate (eGFR) and serum creatinine), proteinuria, and metabolic parameters, were retrieved retrospectively.
Results: Data of six non-diabetic patients with glomerular disorders (five with IgA nephropathy, one with membranous nephropathy) treated at a tertiary care center were collected. An initial decline in eGFR was observed at two weeks post-initiation of dapagliflozin, followed by significant recovery at six months (Day 14: 38.83 ± 9.21 ml/min/1.73 m² vs. Day 180: 44.83 ± 9.78 ml/min/1.73 m²; P = 0.0052). Proteinuria demonstrated progressive reduction across a six-month duration. Lipid profile analysis indicated a reduction in triglycerides but no significant changes in total cholesterol. No adverse events were reported.
Conclusion: Dapagliflozin was well tolerated and associated with improvements in renal function and proteinuria in non-diabetic CKD patients with autoimmune glomerular disorders. These findings support the advantages of…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.